DexCom (DXCM) inventory plummets Friday morning — wearing into the marketplace open — after lacking 2nd quarter earnings estimates and decreasing its full-year earnings steerage. The corporate manufactures and distributes glucose tracking methods utilized in treating diabetes.Seana Smith and Jared Blikre damage down DexCom’s profits figures, how GLP-1 weight-loss drug tendencies is also impacting it, and the way analyst groups are reassessing their outlook at the inventory.For extra knowledgeable perception and the newest marketplace motion, click on right here to look at this complete episode of Morning Transient.This submit used to be written by means of Luke Carberry Mogan.
